European SPC filing strategy protects valuable IP exclusivity for pharma giant
As the foundation of AstraZeneca’s respiratory biologics portfolio, targeting the underlying causes of respiratory illnesses, Fasenra® (benralizumab) is a crucial product for this multinational client.